A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS

Neurology

Volumn 73, Issue 22, 2009, Pages 1842-1848

  Martinelli, V ^a   Rocca, M A ^a,b   Annovazzi, P ^a   Pulizzi, A ^a   Rodegher, M ^a   Boneschi, F Martinelli ^a   Scotti, R ^a   Falini, A ^a   Sormani, M P ^c   Comi, G ^a   Filippi, M ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Division of Neuroscience   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; METHYLPREDNISOLONE; OMEPRAZOLE; SUCRALFATE; DIAGNOSTIC AGENT; NEUROPROTECTIVE AGENT;

ADULT; ADVERSE OUTCOME; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEARTBURN; HICCUP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; IMAGE ANALYSIS; INSOMNIA; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT COURSE THERAPY; SIDE EFFECT; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; BRAIN; DISABILITY; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; NONPARAMETRIC TEST; ORAL DRUG ADMINISTRATION; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; TIME;

ADMINISTRATION, ORAL; ADULT; BRAIN; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; ROC CURVE; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 73349112230     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c3fd5b     Document Type: Article

References (39)

1. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994; 44:1-4.
2. Leary SM, Potrer B, Thompson A. Multiple sclerosis: diagnosis and management of acute relapses. Postgrad Med J 2005;81:302-308.
3. Gelati M, Corsini E, De Rossi M, et al. Methylpred-nisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis. Arch Neurol 2002;59:774-780.
4. Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose methylprednisone. Mult Scler 2002;8:415-419.
5. Compston DAS, Milligan NM, Hughes PJ, et al. A double blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: laboratory results. J Neurol Neurosurg Psychiatry 1987;50:517-522.
6. Richert ND, Ostuni JL, Bash CN, et al. Interferon beta 1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001;7:49-58.
7. Hellwig K, Stein FJ, Przuntek H, Muller T. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol 2004;4:18-22.
8. Droogan AG, Crockard AD, Mc Millan SA, et al. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in multiple sclerosis. Neurology 1998;50:224-229.
9. Sellebjerg F, Christiansen M, Jensen J, et al. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 2000;7: 281-289.
10. Martinez-Càceres EM, Barrau MA, Brieva L, et al. Treatment with methylprednisolone in relapses of multiple sclerosis: immunological evidence of immediate and shot-term, but not long-lasting effects. Clin Exp Immunol 2002;127:165-171.
11. Sloka JS, Stefanelli M. The mechanism of action of meth-ylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425-432.
12. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled trials. J Neurol 2000;247:435-442.
13. Miller DM, Weinstock-Guttman B, Bethoux F, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000;6:267-273.
14. Sellebjerg F, Barnes D, Filippini G, et al. EFNS guidelines on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005;12:939-946.
15. Barkhof F, Hommes OR, Scheltens P, et al. Quantitative MRI changes in gadolinium DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-1222.
16. Zivadinov R, Zorzon M, De Masi R, et al. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci 2008;267:28-35.
17. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Co-chrane database Syst. Rev 4 CD001331 2000.
18. Perumal JS, Caon C, Hreha S, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008;15:677-680.
19. Barkhof F, Tas MW, Frequin ST, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiol 1994;36:382-387.
20. Oliveri RL, Valentino P, Russo C, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998;50: 1833-1836.
21. Alam SM, Kyriakides T, Lowden M, et al. Methylpred-nisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220.
22. Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906. (Pubitemid 27139818)
23. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-534.
24. Sellebjerg F, Jensen CV, Larsson HB, Frederiksen JL. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler 2003;9:102-107.
25. Metz LM, Sabuda D, Hilsden RJ, Enns R, Meddings JB. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology 1999;53:2093-2096.
26. Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in Multiple Sclerosis. Neurology 2004;63:1079-1080.
27. Pitzalis C, Sharrack B, Gray IA, et al. Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J Neuroimmunol 1997;74:62-68.
28. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for Multiple Sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
29. Kurtzke JF. Rating neurological impairment in multiple sclerosis: en Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
30. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
31. Kople S, Heesen C, Kasper J, Muhlhauser I. Steroid treatment for relapses in multiple sclerosis-the evidence urges shared decision-making. Acta Neurol Scand 2004; 110:1-5.
32. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34: 661-669.
33. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969.
34. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
35. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylpred-nisolone in acute optic neuritis. Neurology 1999;52:1479-1484.
36. Van Winsen LM, Muris DF, Polman CH. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab 2005;90:734-740.
37. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33: 480-489.
38. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. European/Canadian Glatiramer Acetate Study Group: Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733.
39. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-683.